-

05:35:50 AM

EVAX Stock News

EVAX - Evaxion Biotech A/S

05/17/22 2:00 AM

Nasdaq : EVAX

managementlow float

Inversago Pharma Appoints Glenn S. Vraniak as Chief Financial Officer

Inversago Pharma Inc., a clinical stage biotech company with a unique portfolio of CB1 inverse agonists, today announces the appointment of Glenn S. Vraniak to the position of Chief Financial Officer, effective immediately. Before joining Inversago, Mr. Vraniak served as Chief Financial Officer of Evaxion Biotech A/S, an AI enabled immuno-oncology company...

RHEA-AI

very positive

05/11/22 7:30 AM

Nasdaq : EVAX

earningslow float

Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update

Received regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanoma Completed recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving first dose Announced publication on personalized therapy with EVX-01 in patients with

RHEA-AI

positive

05/10/22 7:30 AM

Nasdaq : EVAX

clinical triallow float

Evaxion Biotech Announces Successful Production of Personalized Cancer Immunotherapies in Phase 1/2a Clinical Trial for EVX-02

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today that it has

RHEA-AI

neutral

04/29/22 12:15 PM

Nasdaq : EVAX

conferenceslow float

Evaxion Biotech to Host Q1 2022 Corporate Update Conference Call & Webcast on May 11

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will present its first-quarter 2022 financial

RHEA-AI

neutral

04/26/22 8:45 AM

Nasdaq : PSNL, EVAX

Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma

Evaxion Biotech A/S and Personalis announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2 b trial to evaluate the efficacy and safety of Evaxion’ s personalized cancer immunotherapy EVX-01. That means a higher precision in the therapy than the standard of care treatments out there,” said...

RHEA-AI

neutral

04/06/22 7:30 AM

Nasdaq : EVAX

low float

Evaxion Biotech Hosting Key Opinion Leader Webinar on Metastatic Melanoma and Personalized Cancer Immunotherapies

Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, announced today that it will host a key

RHEA-AI

neutral

03/22/22 6:30 AM

Nasdaq : EVAX

earningslow float

Evaxion Biotech Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Completed follow-on public offering (FPO) of 3,942,856 ordinary shares represented by American Depositary Shares (ADSs) raising net proceeds of $24.9 million after deducting underwriting discounts, commissions and other offering expenses Announced clinical trial collaboration and supply agreement

RHEA-AI

positive

03/14/22 7:00 AM

Nasdaq : EVAX

low float

Evaxion Biotech Strengthens Management Team with Two Senior Appointments

Evaxion Biotech A/S (NASDAQ: EVAX) is a clinical-stage biotechnological company specializing in the development of AI-powered immunotherapies to improve the lives of patients with cancer and infectious diseases. Evaxion Biotech announced

RHEA-AI

very positive

03/07/22 7:30 AM

Nasdaq : EVAX

clinical triallow float

Evaxion Biotech Completes Recruitment for Phase 1/2a Clinical Trial for EVX-02

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, has now finalized recruitment for Phase 1/2a clinical trial of EVX-02 in adjuvant melanoma patients. The

RHEA-AI

neutral

01/26/22 7:30 AM

Nasdaq : EVAX

clinical triallow float

Evaxion Biotech Announces Publication of Clinical Data of EVX-01 Heading into Phase 2b in Collaboration with Merck

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies to improve the lives of patients with cancer and infectious diseases, announced today the publication of a

RHEA-AI

neutral

EVAX Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.evaxion-biotech.com
Security nameEvaxion Biotech A/S - ADR
Issue typead
SectorManufacturing
Sic code2836
Employees2021

About Evaxion Biotech A/S

Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer and infectious diseases. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates which currently includes three patient-specific cancer immunotherapies, two of which are in Phase I/IIa clinical development. In addition, Evaxion is advancing a portfolio of vaccines to prevent bacterial and viral infections with one program currently in preclinical development against S. aureus (including Methicillin-resistant S. aureus. or MRSA) induced skin and soft tissue infections.